Alphatec Holdings, Inc. (NASDAQ:ATEC) Short Interest Down 10.3% in November

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) saw a large drop in short interest in November. As of November 15th, there was short interest totalling 10,590,000 shares, a drop of 10.3% from the October 31st total of 11,810,000 shares. Based on an average trading volume of 2,260,000 shares, the days-to-cover ratio is currently 4.7 days.

Institutional Investors Weigh In On Alphatec

Large investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new stake in shares of Alphatec in the 3rd quarter valued at about $69,000. Net Worth Advisory Group bought a new stake in shares of Alphatec during the third quarter valued at approximately $76,000. Comerica Bank raised its position in shares of Alphatec by 64.8% during the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company's stock worth $89,000 after purchasing an additional 2,534 shares during the period. Van ECK Associates Corp lifted its holdings in shares of Alphatec by 57.0% in the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company's stock worth $99,000 after purchasing an additional 6,998 shares in the last quarter. Finally, Tempus Wealth Planning LLC acquired a new stake in Alphatec in the 3rd quarter valued at $107,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Stock Up 1.1 %

Shares of NASDAQ:ATEC traded up $0.11 during midday trading on Friday, reaching $10.48. The company's stock had a trading volume of 636,537 shares, compared to its average volume of 2,043,686. The firm has a 50 day moving average price of $7.11 and a two-hundred day moving average price of $8.20. Alphatec has a fifty-two week low of $4.88 and a fifty-two week high of $17.34. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ATEC shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research report on Thursday, October 31st. Barclays raised their price objective on shares of Alphatec from $19.00 to $20.00 and gave the company an "overweight" rating in a report on Tuesday, November 19th. Needham & Company LLC restated a "buy" rating and issued a $13.00 price target on shares of Alphatec in a research report on Thursday, October 31st. Lake Street Capital dropped their price target on shares of Alphatec from $32.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, September 3rd. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Friday, August 30th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $17.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.